SOURCE: BioPharmetics, Inc.

April 24, 2006 08:31 ET

BioPharmetics, Inc. Gains Significant Market Share in South Africa

NORTH HOLLYWOOD, CA -- (MARKET WIRE) -- April 24, 2006 -- BioPharmetics, Inc. (OTC: BPMT) announced the company has increased sales dramatically into South Africa through their distributor, Destiny Cosmetics. The company recently received a high 5-figure order with several more scheduled over the next 4 months.

"The market in South Africa is starting to show tremendous promise for the company," stated Mr. Paul D. Lisenby, CEO of BioPharmetics, Inc. Mr. Lisenby goes on to say, "The work Destiny Cosmetics and Ms. Fenella Lambert has done is truly remarkable. Our products have been featured in Heat, Essentials, and Absolute Nails magazines over the past several months. This has brought the company's products an exceptional amount of exposure which translates into sales. We fully expect the South African market to bring in upwards of $500,000 in sales this year and possibly more. Destiny Cosmetics is in preliminary talks with several of the largest retail chains in the country to carry our products on a national level. This could propel our sales to over $1 million."

For more information about all of BioPharmetics, Inc. products, please visit the website at

About BioPharmetics, Inc. (OTC: BPMT)

BioPharmetics, Inc. is a manufacturer and distributor of quality pharmaceutical, cosmetic, and anti-aging products. The company has three divisions: biotechnology, pharmaceuticals, and cosmetics/cosmeceuticals, working in unison to develop, manufacture, and distribute, high-quality products in the retail, wholesale, and professional markets. Brands currently offered include Toma™, Isseo™, Molo Africa™, Micha™, and Natural Angel™. BioPharmetics, Inc. also private labels many brands of cosmetics and Cosmeceuticals for salons and retail stores as well as compounding specialized prescriptions for doctors nationwide.

Safe Harbor

This press release contains or may contain forward-looking statements such as statements regarding the Company's growth and profitability, growth strategy, liquidity and access to public markets, operating expense reduction, and trends in the industry in which the Company operates. The forward-looking statements contained in this press release are also subject to other risks and uncertainties, including those more fully described in the Company's filings with the Securities and Exchange Commission. The Company assumes no obligation to update these forward-looking statements to reflect actual results, changes in risks, uncertainties or assumptions underlying or affecting such statements, or for prospective events that may have a retroactive effect.

Contact Information

  • Contact:
    FutureTechIR for BioPharmetics
    Investor Relations
    (817) 812-2105 or 727-417-9338